All R&D articles – Page 4
-
BusinessTwo way traffic for Chinese drug licensing
Western companies are seeing more value in Chinese innovation
-
Business
Gas specialist branches out into carbon nanotubes
Linde group launches ink made with long, individual tubes
-
Business
Data-sharing partnership for drug discovery
Collaborative project aims to assist medicinal chemistry efforts
-
Business
Russian investment vehicle sets sights on innovative drugs
Rusnano hopes to make a killing by investing in new technologies in the pharmaceutical sector
-
Business
AstraZeneca partners with Moderna for $240 million
Pharma company sheds more jobs and backs messenger RNA therapeutics
-
Business
Return on drug R&D dropping
The pharma industry is getting less and less return on investment in R&D but trend seems to be bottoming out
-
Business
Drug R&D costs rising
Review from UK consultancy suggests ten-fold increase in per medicine R&D costs over last 30 years
-
Business
What lies within
Bayer boss Marijn Dekkers aims to increase impact of good R&D across different internal units
-
Business
Bayer and Evotec team up on endometriosis
German collaboration aims to develop three drug candidates in five years
-
Business
Dow tax case raises R&D questions
US court blocks Dow attempt to recoup costs under the R&D tax credit scheme
-
Business
Crowdsourcing science site to launch
Marblar aims to find uses for neglected patents by ‘gamifying’ the technology transfer process
-
Business
Alzheimer's drug flops in Phase III
Solanezumab from Eli Lilly missed the cognitive and functional primary endpoints of the trials
-
Opinion
Monopoly money
Dean Baker says it’s time to start talking seriously about the way in which pharma is funded
-
Business
The future of PVC production?
Commercial interest in a semi-continuous approach seems to be on the rise
-
Business
Coca-Cola collaborates on bio-PET project
Global drinks giant Coca-Cola is teaming up with Ford, Heinz, Nike and Procter & Gamble to increase the use of bio-based polyethylene terephthalate
-
News
Pharma firms see mixed fortunes in Quebec
Canada’s pharmaceutical and life sciences hub hit by cutbacks as effects of global slowdown continue to be felt
